TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at SunTrust Banks lowered their Q3 2017 earnings per share estimates for TG Therapeutics in a research note issued to investors on Wednesday. SunTrust Banks analyst Y. Suneja now forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.45). SunTrust Banks also issued estimates for TG Therapeutics’ Q4 2017 earnings at ($0.47) EPS, FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($0.75) EPS and FY2021 earnings at $0.08 EPS.

TGTX has been the topic of several other research reports. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Thursday, May 18th. Zacks Investment Research cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.67.

WARNING: “Q3 2017 Earnings Estimate for TG Therapeutics, Inc. (TGTX) Issued By SunTrust Banks” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/q3-2017-earnings-estimate-for-tg-therapeutics-inc-tgtx-issued-by-suntrust-banks/1471782.html.

Shares of TG Therapeutics (TGTX) opened at 10.10 on Friday. The company’s market capitalization is $622.73 million. The firm has a 50-day moving average price of $10.95 and a 200 day moving average price of $9.95. TG Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 162.02% and a negative net margin of 68,806.59%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million.

Several hedge funds have recently bought and sold shares of the company. Bank of Montreal Can purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $443,000. Two Sigma Securities LLC purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $325,000. North Star Investment Management Corp. boosted its stake in shares of TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 11,000 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $1,291,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $811,000. 45.68% of the stock is owned by hedge funds and other institutional investors.

In other news, CFO Sean A. Power sold 59,976 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $11.09, for a total value of $665,133.84. Following the completion of the sale, the chief financial officer now owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.70% of the stock is owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.